 Home > Active Ingredient News > Study of Nervous System > Neurology-progressive multiple sclerosis, effective treatment may reduce its recurrence

Neurology-progressive multiple sclerosis, effective treatment may reduce its recurrence

 Last Update: 2021-08-03
 Source: Internet
 Author: User

Tags

hazard class 2

low aluminum antiperspirant

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Although the use of disease modifying therapy (DMT) has changed the long-term prognosis of patients with remission-relapsing multiple sclerosis (RRMS), its prospects in the treatment of secondary progressive multiple sclerosis (SPMS) But more cautious
.

However, clinicians need to consider treating SPMS patients, especially when there is evidence of significant inflammatory activity

For the first time in more than a decade, a new treatment that has the potential to reduce long-term disability has been authorized for the treatment of SPMS
.

In the EXPAND test, siponimod (siponimod)

Immunity in achieving these benefits, high efficacy of treatment is superior to the low efficacy of the treatment is uncertain

Patients with active SPMS who received high-efficiency treatment had a lower recurrence frequency than those who received low-efficiency treatment (hazard ratio [HR] 0.
7, P=0.
006)

The significance of this study lies in the discovery that among SPMS patients undergoing treatment, high-efficiency therapy is superior to low-efficiency therapy in reducing the recurrence of active SPMS patients, but not for inactive SPMS patients
.

However, more effective treatments have no advantage in reducing the progression of disability in this patient population

In SPMS patients receiving treatment, high-efficiency therapy is better than low-efficiency therapy in reducing the recurrence of active SPMS patients, but for inactive SPMS patients, it is not.
In SPMS patients receiving treatment, high-efficiency therapy is reducing activity The recurrence of SPMS patients is better than ineffective therapies, but not for inactive SPMS patients

Original source:
Roos I, Leray E, Casey R, Horakova D, Havrdova E, Izquierdo G, Madueño SE, Patti F, Edan G, Debouverie M, Pelletier J, Ozakbas S, Amato MP, Clavelou P, Grammond P, Boz C , Buzzard K, Skibina O, Ciron J, Gerlach O, Grand'Maison F, Lechner-Scott J, Malpas MPsych CliNeuro C, Butzkueven H, Vukusic S, Kalincik T; MSBase and OFSEP Study Groups.

Effects of High and Low Efficacy Therapy in Secondary Progressive Multiple Sclerosis.
Neurology.
2021 Jun 30:10.
1212/WNL.
0000000000012354.
doi: 10.
1212/WNL.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.